October 30th 2020, 9:45pm
Researchers conducting broad next-generation sequencing discovered more actionable variants in patients and families than they would have otherwise; they did so by using a universal approach, rather than sticking with clinical guidelines.
October 29th 2020, 11:30pm
The FDA has approved new indications for Foundation Medicine's liquid biopsy assay and also its tissue-based companion diagnostic for solid tumors.
October 23rd 2020, 6:45pm
The study describes how RNA sequencing and DNA sequencing for selected genes were performed simultaneously to evaluate gene expression and alterations in order to predict tumor origin.
October 19th 2020, 10:00am
The launch comes as major cancer research organizations are calling for ways to increase diversity in clinical trials.
October 17th 2020, 8:00pm
A recent analysis illustrated how a combination of different genomic approaches discovered actionable alterations in 44% of patients with metastatic breast cancer.
October 9th 2020, 5:30pm
The researchers, from a medical genetics firm, said the findings illustrate the usefulness of germline analysis for the right patient.
October 8th 2020, 2:00pm
Blythe Adamson, PhD, MPH, of Flatiron Health, discusses study results she presented at the annual American Society of Clinical Oncology meeting on the use of immune checkpoint inhibitors in end-of-life care
October 3rd 2020, 5:00pm
Next-generation sequencing (NGS) of cell-free DNA (cfDNA) may improve diagnostic testing in advanced lung cancer.
October 1st 2020, 6:00pm
Andre Goy, MD, of John Theurer Cancer Center, discussed what we’ve learned from existing chimeric antigen receptor T (CAR T)-cell therapies in managing cytokine responses.
September 21st 2020, 8:37pm
The opportunity that precision medicine presents in the field of oncology will be further discussed during this year’s Patient-Centered Oncology Care® 2020 virtual meeting.
